STAT

Sarepta halts early-stage gene therapy trial for DMD

A stray DNA fragment was found "in connection with routine quality assurance testing" of the plasmids used in the company's gene therapy.

Sarepta Therapeutics’ clinical trial for a gene therapy to treat Duchenne muscular dystrophy has been paused by the Food and Drug Administration because some of the materials used in the treatment weren’t as they should be, the company announced Wednesday.

A stray

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readSelf-Improvement
Opinion: Quitting Smoking Is Hard. Mindfulness Hacks The Habit Loop, Offering A New Approach
Smoking hijacks the brain's reward-based learning system. Each time a smoker smokes, it reinforces a brain pathway that says, "This is great, do it again." Mindfulness techniques can break the…
STAT5 min readSociety
After Ebola Spills Into Uganda, WHO Decides Against Emergency Declaration
The Ebola outbreak in the Democratic Republic of the Congo still doesn’t constitute a global health emergency, the WHO said Friday.
STAT3 min readSociety
Opinion: Shopping Blindly For Post-acute Care Is A Recipe For Disaster
The notion that sick, frail, or elderly patients and their families can somehow figure out on their own the best choice for post-acute care must be discarded.